(NAB)-Paclitaxel

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

106 Suppliers, 75 USDMF, 29 CEP/COS, 10 JDMF, 8 EU WC, 23 KDMF, 19 NDC API, 38 Listed Suppliers

DEVELOPMENTS

320 Drug(s) in Development

320 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

17 Suppliers

17 Suppliers

DOSSIERs // Finished Dosage Forms

307 Dossiers, 20 FDA Orange Book, 88 Europe, 5 Canada, 8 Australia, 131 South Africa, 55 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - 6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - 100MG/VIAL

RELATED EXCIPIENT COMPANIES

Suppliers, 2 BASF, 1 Corel Pharma Chem, 1 Nanjing Bold Chemical, 1 Nanjing Well Pharmaceutical

EXCIPIENTS BY APPLICATIONS

3 Solubilizers, 2 Parenteral, 2 API Stability Enhancers, 1 Emulsifying Agents, 1 Granulation, 1 Topical

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 71 Finished Drug Prices

MARKET PLACE

31 APIs, 26 DOSSIERS // FDF

PATENTS

21 US Patents, 8 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 4 USP, 16 Others

DIGITAL CONTENT

6 Data Compilation & Company Tracker #PharmaFlow, 262 News

Annual Sales of Nab-paclitaxel reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

(NAB)-Paclitaxel

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

106 Suppliers

75 USDMF

29 CEP/COS

10 JDMF

8 EU WC

23 KDMF

19 NDC API

38 Listed Suppliers

DEVELOPMENTS

320 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

17 Suppliers

DOSSIERs // Finished Dosage Forms

307 Dossiers

20 FDA Orange Book

88 Europe

5 Canada

8 Australia

131 South Africa

55 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - 6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INTRAVENOUS - 100MG/VIAL

RELATED EXCIPIENT COMPANIES

Suppliers

2 BASF

1 Corel Pharma Chem

1 Nanjing Bold Chemical

1 Nanjing Well Pharmaceutical

EXCIPIENTS BY APPLICATIONS

3 Solubilizers

2 Parenteral

2 API Stability Enhancers

1 Emulsifying Agents

1 Granulation

1 Topical

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

71 Finished Drug Prices

MARKET PLACE

31 APIs

26 DOSSIERS // FDF

PATENTS

21 US Patents

8 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM

4 USP

16 Others

DIGITAL CONTENT

6 Data Compilation & Company Tracker #PharmaFlow

262 News

(NAB)-Paclitaxel

Bristol Myers Squibb

Paclitaxel Protein Bound

Abraxane

Oncology

USD

1,004

811

1,004

811

193

24

Otsuka

Paclitaxel Protein Bound

Abraxane

Oncology

YEN

INJECTABLE;INJECTION - 6MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons